Your browser doesn't support javascript.
loading
The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model.
van Riet, Sander; Julien, Anais; Atanasov, Andrea; Nordling, Åsa; Ingelman-Sundberg, Magnus.
Affiliation
  • van Riet S; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden.
  • Julien A; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
  • Atanasov A; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden.
  • Nordling Å; Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
  • Ingelman-Sundberg M; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden.
Hepatol Commun ; 8(3)2024 03 01.
Article in En | MEDLINE | ID: mdl-38358377
ABSTRACT

BACKGROUND:

The prevalence of NAFLD is rapidly increasing. NAFLD can progress to NASH, fibrosis, cirrhosis, and HCC, which will soon become the main causes of liver transplantation. To date, no effective drug for NASH has been approved by the Food and Drug Administration. This is partly due to the lack of reliable human in vitro models. Here, we present a novel human liver spheroid model that can be used to study the mechanisms underlying liver fibrosis formation and degradation. METHODS AND

RESULTS:

Such spheroids, which contain hepatocytes, stellate cells, KC, and LSECs, spontaneously develop fibrosis that is exacerbated by treatment with free fatty acids. Conditioned medium from activated LSECs caused similar activation of fibrosis in spheroids containing primary human hepatocyte and NPCs, indicating the action of soluble mediators from the LSECs. Spheroids containing LSECs treated with free fatty acids produced tissue inhibitor of metalloproteinases inhibitor 1, a matrix metalloproteinases inhibitor important for fibrosis progression. Tissue inhibitor of metalloproteinases inhibitor 1 knockdown using siRNA led to a reduction in collagen and procollagen accumulation, which could be partially rescued using a potent matrix metalloproteinases inhibitor. Interestingly, tissue inhibitor of metalloproteinases inhibitor 1 was found to be expressed at higher levels, specifically in a subtype of endothelial cells in the pericentral region of human fibrotic livers, than in control livers.

CONCLUSION:

Potential anti-NASH drugs and compounds were evaluated for their efficacy in reducing collagen accumulation, and we found differences in specificity between spheroids with and without LSECs. This new human NASH model may reveal novel mechanisms for the regulation of liver fibrosis and provide a more appropriate model for screening drugs against NASH.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Non-alcoholic Fatty Liver Disease / Liver Neoplasms Type of study: Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Hepatol Commun Year: 2024 Type: Article Affiliation country: Sweden

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Non-alcoholic Fatty Liver Disease / Liver Neoplasms Type of study: Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Hepatol Commun Year: 2024 Type: Article Affiliation country: Sweden